Vaxcyte Inc (PCVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vaxcyte Inc (PCVX) has a cash flow conversion efficiency ratio of -0.186x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-513.10 Million) by net assets ($2.76 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Vaxcyte Inc (PCVX) market capitalisation for the company's overall valuation and market capitalisation.
Vaxcyte Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Vaxcyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vaxcyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaxcyte Inc ranked by their cash flow conversion efficiency. See Vaxcyte Inc (PCVX) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TG Therapeutics Inc
NASDAQ:TGTX
|
0.035x |
|
China Minmetals Rare Earth Co Ltd
SHE:000831
|
0.033x |
|
Columbia Banking System Inc
NASDAQ:COLB
|
0.039x |
|
Piraeus Financial Holdings S.A
AT:TPEIR
|
0.109x |
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
-0.159x |
|
Oil India Limited
NSE:OIL
|
0.054x |
|
Compeq Manufacturing Co Ltd
TW:2313
|
0.043x |
|
Abivax SA
PA:ABVX
|
-0.118x |
Annual Cash Flow Conversion Efficiency for Vaxcyte Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Vaxcyte Inc from 2017 to 2025. View latest Vaxcyte Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.69 Billion | $-655.58 Million | -0.244x | -78.29% |
| 2024-12-31 | $3.31 Billion | $-452.63 Million | -0.137x | +42.77% |
| 2023-12-31 | $1.24 Billion | $-296.79 Million | -0.239x | -33.74% |
| 2022-12-31 | $953.61 Million | $-170.60 Million | -0.179x | +58.14% |
| 2021-12-31 | $284.02 Million | $-121.39 Million | -0.427x | -217.02% |
| 2020-12-31 | $345.84 Million | $-46.63 Million | -0.135x | -130.42% |
| 2019-12-31 | $-106.37 Million | $-47.15 Million | 0.443x | -16.02% |
| 2018-12-31 | $-57.73 Million | $-30.47 Million | 0.528x | +109219.53% |
| 2017-12-31 | $30.94 Million | $-14.96K | 0.000x | -- |
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more